MANAGEMENT OF GUILLAIN BARRÉ SYNDROME IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
Keywords:
Community Acquired Pneumonia, Gullain Barre Syndrome, Respiratory FailureAbstract
Purpose: Gullain Barre Syndrome (GBS) is a sub-acute inflammatory demyelinating polyneuropathy which often triggered by a preceding acute infection that mainly manifests as paresthesia, progressive bilateral and relatively symmetric weakness of the limbs that progresses over days to weeks. The purpose of this study is to determining management of guillain barr syndrome in patients with community acquired pneumonia
Methodology: We presented a case of 41 years old male, presented with dyspnea and weakness in bilateral upper and lower limbs. The study was determining early signs of acute respiratory failure in patient, intubation with mechanical ventilation support was done and admitted in the ICU.
Findings: Mortality rate has varied between 1-18% and usually attributable to pneumonia, sepsis, adult respiratory distress syndrome, or pulmonary embolism. In the current study, after the patient was aggressively treated with broad spectrum antibiotics, plasmapheresis and was supported by mechanical ventilation in the ICU, the patient started to show improvement on second day and progressed well. The patient then was discharged from the ICU on 11th day of admission.
Unique contribution to theory, practice and policy: An aggressive management of respiratory failure with appropriate mechanical ventilation and antibiotics in Community Acquired Pneumonia (CAP) patients results in better patient states and faster recovery. From the current study, we recommend healthcare practitioners to perform an early aggressive management including mechanical ventilation and broad-spectrum antibiotics administration for GBS patient with respiratory failure and CAP.
Downloads
References
Borse, H.P.R., Avate, A., Palasdeokar, N. (2016). Guidelines on the Use of Therapeutic Apheresis in Clinical Practice"”Evidence Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. JAPI, 65,1.
Bhadade, R., deSouza, R., Bawaskar, P. (2019). Mortality Outcome in Patients of Guillian Barre Syndrome. A single Center Study. International Journal of Contemporary Medical Research [IJCMR],6 Issue 6, F17-F18
Brochard, L. (2003). Mechanical ventilation: invasive versus noninvasive. European Respiratory Journal, 22(47 suppl), 31s-37s.
Dimachkie, M. M., & Barohn, R. J. (2013). Guillain-Barr syndrome and variants. Neurologic clinics, 31(2), 491-510.
Kerr, J., Quinti, I., Eibl, M., Chapel, H., Späth, P. J., Sewell, W. A., ... & Peter, H. H. (2014). Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Frontiers in immunology, 5, 629.
Kishore, C. K., Vijayabhaskar, J., Vishnu Vardhan, R., Sainaresh, V. V., Sriramnaveen, P., Sridhar, A. V. S. S. N., ... & Siva Kumar, V. (2014). Management of Guillain-Barre syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India. Renal failure, 36(5), 732-736.
Khatib, H.E., Naous, A., Ghanem, S., Dbaibo, G., Rajab, M. (2017). Case report: Guillain-Barre syndrome with pneumococcus - A new association in pediatrics. IDCases, 11, 36-38
Meena, A. K., Khadilkar, S. V., & Murthy, J. M. K. (2011). Treatment guidelines for Guillain-Barr syndrome. Annals of Indian Academy of Neurology, 14(Suppl1), S73.
Mohamed, E. E., & Abd Allah, A. E. A. (2019). Assessment of clinical applicability of pneumonia scores to determine patients with community-acquired pneumonia who will need hospital admission. The Egyptian Journal of Chest Diseases and Tuberculosis, 68(2), 224.
Morgan, A. J., & Glossop, A. J. (2016). Severe community-acquired pneumonia. Bja Education, 16(5), 167.
Nobile-Orazio, E. (2018). The complement story in Guillain-Barre syndrome: from pathogenesis to therapy. The Lancet Neurology, 17(6), 483-485.
Orlikowski, D., Sharshar, T., Porcher, R., Annane, D., Raphael, J. C., & Clair, B. (2006). Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barr syndrome. Intensive care medicine, 32(12), 1962-1969.
Ott, S. R., Hauptmeier, B. M., Ernen, C., Lepper, P. M., Nüesch, E., Pletz, M. W., ... & Bauer, T. T. (2012). Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. European respiratory journal, 39(3), 611-618.
Prasad, H. B., Borse, R. T., Avate, A. N., & Palasdeokar, N. (2017). Prognostic indicators of response to plasmapheresis in patients of Guillain Barre syndrome. J Assoc Physicians India, 65(4), 32-36.
Robert, K. Y., Usuki, S., & Ariga, T. (2006). Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infection and immunity, 74(12), 6517-6527.
Sawelinggi, D., Aryabiantara, W., Wiryana, M. (2019). Penatalaksanaan Guillain Barre syndrome di ICU; sebuah laporan kasus. MEDICINA, 50(2), 304-307
Slupsky, C. M., Cheypesh, A., Chao, D. V., Fu, H., Rankin, K. N., Marrie, T. J., & Lacy, P. (2009). Streptococcus pneumoniae and Staphylococcus aureus pneumonia induce distinct metabolic responses. Journal of Proteome Research, 8(6), 3029-3036.
Van Doorn, P. A., Kuitwaard, K., Walgaard, C., van Koningsveld, R., Ruts, L., & Jacobs, B. C. (2010). IVIG treatment and prognosis in Guillain-Barre syndrome. Journal of clinical immunology, 30(1), 74-78.
Wier, J.B. (2008). Guillain Barre syndrome. BMJ, 337, 227-231.
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
